| |
|
Outcomes of Patients Interrupting Glecaprevir/Pibrentasvir Treatment: A Case Series From Clinical Trials
|
| |
| |
Philippe Zamor1, John Dillon2, Douglas Dylla3, David Mutimer4, Reem Ghalib5, Massimo Colombo6, Richard Skoien7, Eric Crown3, Yiran Hu3, Eric Lawitz81Division of Hepatology, Carolinas Healthcare Systems, Charlotte, North Carolina, United States; 2Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, United Kingdom; 3AbbVie Inc., North Chicago, Illinois, United States; 4NIHR Liver Biomedical Research Unit, University of Birmingham, Birmingham, United Kingdom; 5Texas Clinical Research Institute, Arlington, Texas, United States; 6Center for Translational Hepatology Research, Clinical and Research Center Humanitas Hospital, Rozzano, Italy; 7Hepatic Fibrosis Laboratory, QIMR Berghofer Medical Research Institute, Queensland, Australia; School of Medicine, University of Queensland, Queensland, Australia; Department of Gastroenterology and Hepatology, Royal Brisbane and Women’s Hospital, Queensland, Australia; 8The Texas Liver Institute, University of Texas Health San Antonio, San Antonio, Texas, United States
Hep Dart 2019, December 8-12,
2019, Kauai, Hawaii
Reported by Jules Levin
| |
| |
| |
|
|
|
